SecBot SecBot
8-K ·Filed Sep 2, 2026

QURE

uniQure N.V.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001104659-26-104463
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

Monitor FDA acceptance of the BLA (expected within 60 days) and the priority review decision. The upcoming four-year data presentation before end of Q3 2026 could further de-risk the regulatory path. Any FDA rejection or delay would be a significant negative catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

AMT-130

▲ Bullish Named in this 8-K
Impact
Phase
Phase 1/2 (pivotal for accelerated approval)
Time to market
BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
Next catalyst
None dated

What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$46.23
T+0 close · Sep 2, 2026 · via day close
Latest settled
−3.81%
T+5 · $44.47
Vs SPY
−2.85%
α at T+5
Next horizon
T+20
due 7w ago
  1. T+0 · Sep 2 $46.23entry
  2. T+1 · 3mo ago −2.96%α −4.01% · $44.86
  3. T+5 · 2mo ago −3.81%α −2.85% · $44.47
  4. T+20 · due 7w ago Pending
  5. T+52 · todayOpen
  6. T+60 · in 10d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

uniQure announced submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval of its gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, along with a parallel Marketing Authorisation Application (MAA) to the UK MHRA. The submissions are supported by three-year Phase I/II data showing slowed disease progression, and the company has requested priority review, which could shorten the FDA review cycle to six months. This is a major regulatory milestone for a first-in-class therapy addressing a large unmet need, though approval is not guaranteed and the stock has historically underperformed on high-impact events.

Key Facts

  • BLA submitted to FDA for accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease
  • MAA submitted to UK MHRA for the same therapy
  • Priority review requested for the BLA; if granted, FDA review cycle would be six months after the 60-day filing review period
  • Submissions supported by three-year data from Phase I/II study showing slowing of disease progression vs. propensity score-matched external control
  • Company plans to present four-year data analysis from ongoing Phase I/II studies before end of current third quarter
  • Ifezuntirgene inilparvovec holds FDA Breakthrough Therapy and RMAT designations, as well as Fast Track designation

Financial Impact

No financial figures disclosed; potential multi-billion-dollar market opportunity if approved for ~75,000 patients in U.S., EU, and UK with no currently approved disease-modifying therapies

Risk Factors

  • FDA may not accept the BLA for filing or may deny priority review
  • Phase I/II data may be deemed insufficient for accelerated approval; confirmatory study may be required
  • Regulatory decisions in the UK (MHRA) are independent and may differ from FDA

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-104463
Document: qure-20260902xex99d1.htm0001104659-26-104463
Document: 0001104659-26-104463-index-headers.html0001104659-26-104463
Document: 0001104659-26-104463-index.html0001104659-26-104463
Document: 0001104659-26-104463.txt0001104659-26-104463

Track record

38 reports on QURE

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 7/10 No price data
  3. Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  5. Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  6. Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 7/10 Viewing Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
  8. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
  9. Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (10h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026